Puberty Suppressants Trial

Tom Tugendhat Excerpts

Wednesday 17th December 2025 Commons Chamber

[Wes Streeting]

My hon. Friend is absolutely right that we must engage with due care and sensitivity on this issue. I can share with the House that these exchanges, Government policy, what is said by me and others, are followed extremely closely by this group of children and young people, who are extremely online, and by the wider LGBT+ community. My hon. Friend is right that trans people are often at the wrong end of the statistics as victims of hate crime, discrimination and mental ill health. We must always tread carefully when talking about suicide in this context, and bear in mind the warnings of the Government’s adviser on suicide prevention, Professor Louis Appleby, and the way in which that issue has been deployed irresponsibly by critics of the ban on puberty blockers that was put in place—we bear all those things in mind. I do think we have a high-quality trial set up. I do have confidence in the clinicians. We have had a cross-party briefing from the clinical team. I am happy to repeat that exercise, to keep coming back to the House and to arrange briefings for MPs and peers on a cross-party basis so that we can follow this closely, as we should.

[Tom Tugendhat (Tonbridge) (Con)]

I welcome the care with which the right hon. Member has approached much of this, and I appreciate that he has before him some very difficult decisions, especially because of the way the report was written. But I must come back to the simple truth that these are very young children, and decisions will be made for them—I appreciate by parents, taking that element of consent—that are genuinely irreversible. Whatever happens, we will see eight, nine, 10-year-olds grow up to be 18, 20, 25-year-olds—at least we hope we will—who have effectively been experimented on. Some of those children will resent greatly not just the system and their parents, but those who allowed this to happen, and here I identify the Department for Health and Social Care, not necessarily the Secretary of State himself. What provision is he putting in place to ensure that should those children wish to bring legal action against the Department, against those who took these decisions at a time when they were not able to give any form of informed consent, they will be able to have redress and their day in court?

[Wes Streeting]

I first thank the right hon. Member for the way in which he puts his concerns. I know he is concerned about this trial and that he has stated publicly his opposition to it, and I enormously respect the way in which he has done that. These are finely balanced judgments, and I acknowledge that.

The Cass review found that puberty blockers have been prescribed routinely without good evidence for their safety or effectiveness, and that is why a clinical trial was proposed. They are licensed and used safely in much younger children for precocious puberty or in older adults for certain cancers. For adolescents, the interaction with all the different processes of puberty may be very significant, which is why more evidence and a better understanding of their impact is needed in this patient group. Anyone on the trial can choose to stop taking puberty-suppressing hormones and leave the trial at any time; they do not need to give a reason. If a young person decides to stop taking puberty-suppressing hormones, their care in the NHS, including the gender service, will not change in any other way, and their doctors will explain to them and their parents or guardians what treatment options are available.

I know that there are concerns about the longer-term impacts on fertility. Prospective participants will be given comprehensive information on the advantages and potential risks of the hormones, including details about preserving fertility. Doctors will explain the possible long-term consequences and available options. Young people will also be offered consultation with a fertility specialist. The young person and their parent or guardian must clearly demonstrate a full understanding of all these issues—only then, after that, would a clinician sign off on admission to the trial.